Can a single molecule quiet the genetic chaos behind three brain diseases?
Disease control
Recruiting now
This first-in-human trial is testing an experimental drug called VO659 in people with spinocerebellar ataxia type 1, type 3, or Huntington's disease. The drug is designed to target the genetic repeats that cause these conditions, potentially slowing their progression. The study a…
Phase 1/2 • Sponsor: Vico Therapeutics B. V. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC